These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39303724)

  • 1. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.
    Wang X; Fang Y; Liang W; Wong CC; Qin H; Gao Y; Liang M; Song L; Zhang Y; Fan M; Liu C; Lau HC; Xu L; Li X; Song W; Wang J; Wang N; Yang T; Mo M; Zhang X; Fang J; Liao B; Sung JJY; Yu J
    Cancer Cell; 2024 Oct; 42(10):1729-1746.e8. PubMed ID: 39303724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
    Cai L; Chen A; Tang D
    Immunology; 2024 Oct; 173(2):209-226. PubMed ID: 38517066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
    Gao Y; Bi D; Xie R; Li M; Guo J; Liu H; Guo X; Fang J; Ding T; Zhu H; Cao Y; Xing M; Zheng J; Xu Q; Xu Q; Wei Q; Qin H
    Signal Transduct Target Ther; 2021 Nov; 6(1):398. PubMed ID: 34795206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.
    Park HE; Kim JH; Cho NY; Lee HS; Kang GH
    Virchows Arch; 2017 Sep; 471(3):329-336. PubMed ID: 28597080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
    Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
    J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
    Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wu QL; Fang XT; Wan XX; Ding QY; Zhang YJ; Ji L; Lou YL; Li X
    World J Gastroenterol; 2024 Apr; 30(14):2018-2037. PubMed ID: 38681125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status.
    Lee JA; Yoo SY; Oh HJ; Jeong S; Cho NY; Kang GH; Kim JH
    Cancer Immunol Immunother; 2021 Jan; 70(1):47-59. PubMed ID: 32623478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies.
    Han YJ; Shao CY; Yao Y; Zhang Z; Fang MZ; Gong T; Zhang YJ; Li M
    Postgrad Med J; 2024 May; 100(1184):373-381. PubMed ID: 38211949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 18. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment.
    Jia M; Yuan Z; Yu H; Feng S; Tan X; Long Z; Duan Y; Zhu W; Yan P
    Biomed Pharmacother; 2024 Jul; 176():116883. PubMed ID: 38876047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
    Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
    Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.